Bryce B Reeve1,2, Xianming Tan3,4, Ronald C Chen3,5, Deborah S Usinger3, Laura C Pinheiro6. 1. Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina. 2. Center for Health Measurement, Duke University School of Medicine, Durham, North Carolina. 3. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. 4. Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina. 5. Department of Radiation Oncology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina. 6. Division of General Internal Medicine, Weill Cornell Medicine, New York, New York.
Abstract
BACKGROUND: Men diagnosed with localized prostate cancer seek information on how treatment options may impact their health-related quality of life (HRQOL). The authors used latent profile analysis (LPA) to group men according to their symptom burden and functional status and to identify patient characteristics associated with each HRQOL profile. METHODS: Patients completed the Patient-Reported Outcomes Measurement Information System and the Expanded Prostate Index Composite measures 3 months after treatment initiation. Anxiety, depression, fatigue, sleep disturbance, pain, diarrhea, urinary obstruction, urinary incontinence, erectile function, and sex satisfaction were modeled jointly using LPA, and the analysis was adjusted for covariates to examine associations between patient characteristics and profiles. RESULTS: One-third of the 373 men were not non-Hispanic white (26% were black). Four LPA profiles were identified. Men who experienced the "best HRQOL" were less likely to receive treatment, to be older, and to smoke. Men in the second best profile experienced symptoms similar to men in the best HRQOL group but reported poor sexual and urinary function, because they were more likely to receive therapy. The third profile included men with increased symptom burden and poor functioning who were likely to undergo prostatectomy and to have increased comorbidity. The "worst HRQOL" group experienced the worst symptoms and the poorest functioning, and these men were more likely to be younger, to have more comorbidities, and to smoke. CONCLUSIONS: LPA revealed that men who receive the same treatment can experience very different HRQOL impact. Understanding the factors most associated with poorer HRQOL allows clinicians to focus their care on individuals most in need of symptom management and support. Cancer 2018;124:2832-2840.
BACKGROUND:Men diagnosed with localized prostate cancer seek information on how treatment options may impact their health-related quality of life (HRQOL). The authors used latent profile analysis (LPA) to group men according to their symptom burden and functional status and to identify patient characteristics associated with each HRQOL profile. METHODS:Patients completed the Patient-Reported Outcomes Measurement Information System and the Expanded Prostate Index Composite measures 3 months after treatment initiation. Anxiety, depression, fatigue, sleep disturbance, pain, diarrhea, urinary obstruction, urinary incontinence, erectile function, and sex satisfaction were modeled jointly using LPA, and the analysis was adjusted for covariates to examine associations between patient characteristics and profiles. RESULTS: One-third of the 373 men were not non-Hispanic white (26% were black). Four LPA profiles were identified. Men who experienced the "best HRQOL" were less likely to receive treatment, to be older, and to smoke. Men in the second best profile experienced symptoms similar to men in the best HRQOL group but reported poor sexual and urinary function, because they were more likely to receive therapy. The third profile included men with increased symptom burden and poor functioning who were likely to undergo prostatectomy and to have increased comorbidity. The "worst HRQOL" group experienced the worst symptoms and the poorest functioning, and these men were more likely to be younger, to have more comorbidities, and to smoke. CONCLUSIONS:LPA revealed that men who receive the same treatment can experience very different HRQOL impact. Understanding the factors most associated with poorer HRQOL allows clinicians to focus their care on individuals most in need of symptom management and support. Cancer 2018;124:2832-2840.
Authors: Andrea Salonia; Ganesh Adaikan; Jacques Buvat; Serge Carrier; Amr El-Meliegy; Kostas Hatzimouratidis; Andrew McCullough; Abraham Morgentaler; Luiz Otavio Torres; Mohit Khera Journal: J Sex Med Date: 2017-03 Impact factor: 3.802
Authors: Chantal Quinten; Francesca Martinelli; Corneel Coens; Mirjam A G Sprangers; Jolie Ringash; Carolyn Gotay; Kristin Bjordal; Eva Greimel; Bryce B Reeve; John Maringwa; Divine E Ediebah; Efstathios Zikos; Madeleine T King; David Osoba; Martin J Taphoorn; Henning Flechtner; Joseph Schmucker-Von Koch; Joachim Weis; Andrew Bottomley Journal: Cancer Date: 2013-10-11 Impact factor: 6.860
Authors: Ronald C Chen; Ramsankar Basak; Anne-Marie Meyer; Tzy-Mey Kuo; William R Carpenter; Robert P Agans; James R Broughman; Bryce B Reeve; Matthew E Nielsen; Deborah S Usinger; Kiayni C Spearman; Sarah Walden; Dianne Kaleel; Mary Anderson; Til Stürmer; Paul A Godley Journal: JAMA Date: 2017-03-21 Impact factor: 56.272
Authors: Kathryn E Flynn; Bryce B Reeve; Li Lin; Jill M Cyranowski; Deborah Watkins Bruner; Kevin P Weinfurt Journal: Health Qual Life Outcomes Date: 2013-03-11 Impact factor: 3.186
Authors: Joanne W Jang; Michael R Drumm; Jason A Efstathiou; Jonathan J Paly; Andrzej Niemierko; Marek Ancukiewicz; James A Talcott; Jack A Clark; Anthony L Zietman Journal: Cancer Med Date: 2017-05-31 Impact factor: 4.452
Authors: Thi Xuan Mai Tran; Jungeun Park; Joonki Lee; Yuh-Seog Jung; Yoonjung Chang; Hyunsoon Cho Journal: Support Care Cancer Date: 2020-10-15 Impact factor: 3.603
Authors: Blanca Noriega Esquives; Tae K Lee; Patricia I Moreno; Rina S Fox; Betina Yanez; Gregory E Miller; Ryne Estabrook; Mark J Begale; Sarah C Flury; Kent Perry; Shilajit D Kundu; Frank J Penedo Journal: J Behav Med Date: 2022-02-02